Tag Archive | "head and neck cancer"

Review Finds Evidence Lacking for Dry Mouth Remedies

Wednesday, December 28, 2011

0 Comments

Source: Medscape Today December 28, 2011 — There is not enough evidence to recommend any topical therapies for dry mouth, but that does not mean that they do not work, according to investigators who published a review of research on the therapies online December 4 in the Cochrane Library. “There was very little evidence,” said [...]

Continue reading...

Quality-of-Life Outcomes in Transoral Robotic Surgery

Tuesday, December 27, 2011

0 Comments

Source: SAGE Journals Online Abstract Objective. To report long-term, health-related quality-of-life (HRQOL) outcomes in patients treated with transoral robotic surgery (TORS). Study Design. Prospective, longitudinal, clinical study on functional and HRQOL outcomes in TORS. Setting. University tertiary care facility. Subjects and Methods. Patients who underwent TORS were asked to complete a Head and Neck Cancer [...]

Continue reading...

A Planned Neck Dissection is Not Necessary in All Patients with N2-3 Head-and-Neck Cancer After Sequential Chemoradiotherapy

Tuesday, December 13, 2011

0 Comments

Source: DocGuide.com PURPOSE: To assess the role of a planned neck dissection (PND) after sequential chemoradiotherapy for patients with head-and-neck cancer with N2-N3 nodal disease. METHODS AND MATERIALS: We reviewed 90 patients with N2-N3 head-and-neck squamous cell carcinoma treated between 1991 and 2001 on two sequential chemoradiotherapy protocols. All patients received induction and concurrent chemotherapy [...]

Continue reading...

UI professors: HPV editorial misses the mark

Thursday, December 8, 2011

1 Comment

Source: The Daily Iowan The Nov. 29 editorial “Recommend Pap smears, not vaccines, to prevent cervical cancer” completely missed the mark with regard to HPV vaccines. We are researchers and clinicians at the University of Iowa who study and treat HPV and other infectious diseases. It is disturbing to think that the article might dissuade [...]

Continue reading...

Lymphedema Common After Head and Neck Cancer

Tuesday, December 6, 2011

0 Comments

Source: Elsevier Global Medical News   SAN FRANCISCO (EGMN) – Lymphedema is highly common and a source of considerable morbidity among patients who undergo treatment for head and neck cancer, finds a cross-sectional study among 103 survivors. Fully three-fourths had developed some degree of lymphedema, according to results presented at the annual Oncology Congress presented [...]

Continue reading...

Predictors of survival in mucosal melanoma of the head and neck.

Monday, November 14, 2011

0 Comments

Source:MedScape.com Jethanamest D; Vila PM; Sikora AG; Morris LG Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, NY, USA. BACKGROUND: The head and neck is the most common site of mucosal melanoma, a cancer with poor prognosis. In contrast to cutaneous melanoma, mucosal melanoma of the head and neck (MMHN) is uncommon, with [...]

Continue reading...

Although Most Smokers Want to Quit… Only a Fraction Actually Do

Friday, November 11, 2011

0 Comments

Source: The Wall Street Journal Author: Betsy McKay   More than two-thirds of American smokers want to quit, but only a fraction actually do, underscoring a need for more services, messages, and access to medications to help them kick the habit, according to a new government report out today. Nearly 69% of adult smokers wanted to quit [...]

Continue reading...

FDA Approves Cetuximab for Late-Stage Head and Neck Cancer

Wednesday, November 9, 2011

0 Comments

Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with [...]

Continue reading...

FDA Approves Cetuximab for Metastatic Head and Neck Cancer

Tuesday, November 8, 2011

0 Comments

Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is [...]

Continue reading...

The Oral Cancer Foundation Helps Sponsor HPV/Oral Cancer Study

Tuesday, November 1, 2011

0 Comments

Source: Jada.org An increase in the incidence and survival of oropharyngeal cancer in the United States since 1984 can be attributed to the human papilloma-virus (HPV) infection, say researchers in an article published online Oct. 3 in Journal of Clinical Oncology. The results of previous studies have shown that oropharyngeal cancers can be divided into [...]

Continue reading...